Progenics Pharma (PGNX) Misses Q3 EPS by 3c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.52, $0.03 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $53.9 million versus the consensus estimate of $52.9 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelcase (SCS) Reports Preliminary Q3 EPS In-Line with Views, Revs Light
- Oil-Dri Corp. (ODC) Reports Q1 EPS of $0.28
- Vail Resorts (MTN) Misses Q1 EPS by 13c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!